Emergo by UL
a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
- Country
- United States
US
Coverage
| EU | US | |
|---|---|---|
| regulatory-legal | ✓ | ✓ |
Regulatorsfda
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Medical-device reimbursement listing | regulatory-legal | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.